23948sdkhjf
  • {{ window.visitor.corporateClient.name }}
    Corporate solution
    {{ window.visitor.ipAccess.corporateClient.name }}
    {{ window.visitor.corporateClient.name }}

  • Welcome to our Corporate client solution

    Here you can administrate your corporate solutions users.

  • Welcome to your subscription for Life Science Focus

  • Welcome to our Corporate client solution

    Your IP is registered with the company mentioned above and provides access to Life Science Focus.

  • Click here to go to sign-up
Log in or create to bookmark articles
Get access to all content on Life Science Focus
No commitment or card information required
Try Life Science Focus now
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement

Former Novo Nordisk CEO nominated as Lundbeck chair

Lars Fruergaard Jørgensen, former CEO of Novo Nordisk, has been nominated to become the new Chair of the Board at Lundbeck. He is expected to succeed Dorothea Wenzel, who has informed the Board of her intention to step down.
Advertisement

Lars Fruergaard Jørgensen joined Novo Nordisk in 1991 and served as its CEO from 2017 to 2025, when he left the role following a period of growing market challenges and a falling share price.

During his tenure, he led Novo Nordisk through a period of substantial growth. He has more than 30 years of international experience in the pharmaceutical industry and has also served as president of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Advertisement Advertisement
BREAKING
{{ article.headline }}
0.063|